Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 12, 2026 08:05 ET | Source: Recludix Pharma, Inc.

Recludix Pharma Announces Equity Financing to Advance Clinical Development of Novel SH2 Domain Inhibitors

Financing led by institutional investors, with participation from new investor Eli Lilly and CompanyInclusive of this investment, a total of $123 million in equity financing received from...
January 12, 2026 08:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma Announces Dosing of First Subjects in a Phase 1 Study of REX-8756, a Potent and Selective Oral STAT6 Inhibitor, and Achieves Associated $20 Million Milestone Payment Under Collaboration with Sanofi

--Phase 1 study of REX-8756 is well underway following FDA clearance of the Investigational New Drug (IND) application in December 2025 --In preclinical studies, REX-8756 elicited complete, rapid and...
January 08, 2026 08:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma Bolsters Scientific Advisory Board with Acclaimed Leaders in the Fields of Rheumatology, Dermatology and JAK/STAT Biology

SAN DIEGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for inflammatory disease, today...
January 07, 2026 08:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma to Present at the Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for inflammatory disease, today...
December 16, 2025 08:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma Announces FDA Clearance of Investigational New Drug Application for REX-8756, an Oral STAT6 Inhibitor, to Enter into the Clinic

REX-8756 is a potent and selective oral STAT6 inhibitor that has shown complete 100% pathway inhibition and potent efficacy in preclinical models of asthma, acute lung inflammation and...
November 03, 2025 08:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma to Present at Two Investor Conferences in November

SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in the discovery of inhibitors of challenging targets for inflammatory disease, today announced that members of Recludix’s...
September 11, 2025 16:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma to Present at the Stifel 2025 Virtual Immunology and Inflammation Forum

SAN DIEGO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in the discovery of inhibitors of challenging targets for inflammatory disease, today announced that Nancy Whiting, Pharm.D.,...
July 14, 2025 08:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma Announces Strengthening of Leadership Team, Including Promotion of Dr. Brian Hodous to Chief Scientific Officer

--Brian Hodous, Ph.D., promoted to chief scientific officer -- Vivek Kadambi, Ph.D., joins Recludix as senior vice president of non-clinical sciences and CMC -- Kristin Polsenski, M.B.A., expands...
June 02, 2025 07:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma Announces Development Candidate Nomination of First-in-Class Oral STAT6 Inhibitor for Inflammatory Diseases and Achievement of Significant Milestone Under Collaboration with Sanofi

--Completion of GLP toxicology studies associated with a $50 million payment to Recludix under the collaboration with Sanofi -- REX-8756 is a potent and selective oral STAT6 inhibitor that...
May 19, 2025 08:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma Presents Data Demonstrating Potent Efficacy and High Selectivity of a STAT6 Inhibitor in Preclinical Asthma Model

--Efficacy comparable to anti-IL4/IL13 antibody control --Achieved dose-dependent and durable target modulation in vivo without requiring degradation of STAT6 protein --Avoided broad JAK-mediated...